<DOC>
	<DOCNO>NCT00005068</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase I trial determine effectiveness two different regimen combination chemotherapy treat patient metastatic unresectable solid tumor .</brief_summary>
	<brief_title>Combination Chemotherapy In Treating Patients With Metastatic Unresectable Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose irinotecan , fluorouracil , leucovorin calcium ( Saltz regimen vs Mayo regimen ) plus oxaliplatin ( arm I vs arm II ) patient metastatic unresectable solid tumor . II . Determine effect irinotecan disposition oxaliplatin patient . III . Assess development peripheral neuropathy patient Mayo regimen . IV . Determine activity regimens patient metastatic solid tumor . OUTLINE : This dose escalation study . Patients enter one two treatment arm : Arm I ( Saltz regimen ) : Patients receive irinotecan IV 90 minute , leucovorin calcium IV , fluorouracil IV day 1 , 8 , 15 , 22 , follow oxaliplatin IV 2 hour day 1 15 . Courses repeat every 6 week . Arm II ( Mayo regimen ) : Patients receive irinotecan IV 90 minute oxaliplatin IV 2 hour day 1 , follow leucovorin calcium IV fluorouracil IV 90 minute day 2-5 . Courses repeat every 3 week . Cohorts 3-6 patient receive escalate dos fluorouracil ( one two treatment dos arm II ) , one two treatment dos irinotecan oxaliplatin maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose limit toxicity . Patients follow 3 month . PROJECTED ACCRUAL : Up 60 patient accrue study within 8-14 month .</detailed_description>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven metastatic unresectable solid tumor standard curative therapy exist No CNS metastases PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 12 week Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) AST great 5 time ULN Renal : Creatinine normal OR Creatinine clearance least 60 mL/min Cardiovascular : No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmias No New York Heart Association class III IV heart disease Neurologic : No peripheral neuropathy grade 2 great No uncontrolled seizure disorder Other : Not pregnant nursing Fertile patient must use effective contraception No uncontrolled concurrent illness No active infection No history allergy platinum compound , irinotecan , antiemetic , antidiarrheal PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior immunotherapy At least 4 week since prior biologic therapy No concurrent immunotherapy Chemotherapy : At least 4 week since prior chemotherapy ( 6 week since nitrosoureas mitomycin ) recover No great 3 prior chemotherapy regimens metastatic disease No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior pelvic radiotherapy At least 4 week since prior radiotherapy No prior radiotherapy great 25 % bone marrow No concurrent radiotherapy Surgery : Not specify Other : No concurrent antiretroviral therapy HIV positive patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>